What the research shows
Tesamorelin reduced CT-measured visceral fat in a 26-week placebo-controlled trial of people with HIV and abdominal fat accumulation. The trial tested tesamorelin as a single active ingredient. Tesamorelin trial.
In healthy male volunteers, a separate exposure study measured ipamorelin concentrations and the subsequent growth hormone response. It provides information about a short-lived hormonal signal. Neither experiment compared a two-peptide mixture with its individual ingredients. Ipamorelin exposure and growth hormone study.
Documented formats
The source studies describe separate tesamorelin and ipamorelin preparations. They do not document a standardized fixed combination or a validated mixing ratio.
Testing and purity
A blend report needs separate identity and amount measurements for both peptides in the same lot. A combined vial weight gives no information about their relative amounts.
How to read a batch reportQuestions about Tesamorelin + Ipamorelin
Does the Egrifta approval apply to this blend?
Egrifta's reviewed formulation contains tesamorelin as its active ingredient. That approval attaches to the specified product.
What evidence would test a claim of added benefit?
A study would need a defined combination, appropriate single-ingredient controls and a prespecified outcome measured over the same interval.